Struggling Marinus gets a bump out of a positive PhII snapshot

Print 24 January 2017
Arsalan Arif / Endpoints News

A lit­tle more than six months since its stock price was crushed by a failed late-stage pro­gram for its lead­ing — and only — drug, tiny biotech mi­cro­cap Mar­i­nus $MRNS saw its shares shoot up this morn­ing after it of­fered a pos­i­tive Phase II snap­shot on a hand­ful of pa­tients who suf­fer from a rare ge­netic ail­ment.

In­ves­ti­ga­tors flipped the first card of its Phase II hand for ganax­olone in treat­ing CDKL5, which trig­gers se­vere seizures and neu­ro­log­i­cal dam­age among the chil­dren af­flicted by it. One of four pa­tients had to drop out from a lack of re­sponse, but in­ves­ti­ga­tors say that the three oth­ers ex­pe­ri­enced a re­duc­tion in seizures rang­ing from 52% to 88%.

Pre­sent­ing data at the an­nual meet­ing of the Amer­i­can Epilepsy So­ci­ety, re­searchers also added seizure re­sponses and EEG mea­sure­ments for three pa­tients — one with CDKL5 and two with PCD­H19 pe­di­atric epilepsy — un­der­scor­ing a pos­i­tive re­sponse in cut­ting the rate of seizures from base­line.

In­vestors liked what they saw, dri­ving up shares about 40% in morn­ing trad­ing. It was a dif­fer­ent story last June, when the com­pany’s shares dived on the news that ganax­olone had failed a late-stage study for adult focal onset seizures. Its mar­ket cap at the end of day on Fri­day was a frag­ile $22 mil­lion.

It’s early days yet for this study, which is de­signed to en­roll up to 10 pa­tients with each of CDKL5 dis­or­der, Lennox Gas­taut Syn­drome and PCD­H19 pe­di­atric epilepsy.

The drug de­vel­op­ment pro­gram here is sim­i­lar to what Sage has been work­ing on, with a focus on sta­tus epilep­ti­cus as well as post­par­tum de­pres­sion.

Michael G. Chez, the di­rec­tor of Pe­di­atric Neu­rol­ogy Re­search and Pe­di­atric Epilepsy, Sut­ter Neu­ro­science In­sti­tute, said:

“I am im­pressed with the re­spon­der rate and mag­ni­tude of seizure con­trol seen with ganax­olone in the ini­tial CDKL5 pa­tients. The CGIs (clin­i­cal global im­pres­sion scales) are con­sis­tent with seizure con­trol, with re­spon­ders show­ing ‘much im­proved’ under this scale. I look for­ward to fur­ther eval­u­at­ing these chil­dren and see­ing the final re­sults.”

Source

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news